Skip to main content
. 2022 Nov 11;13:1058819. doi: 10.3389/fimmu.2022.1058819

Figure 6.

Figure 6

Reduced death risk at lung cancer, non-cancer and non-lung cancer causes in the immunotherapy era than in the pre-immunotherapy era in patients with metastatic non-small cell lung cancer. Overall three-year death risks for lung cancer, non-cancer and non-lung cancer causes were reduced by 29.2%, 13.7% and 27.8%, respectively.